The Global Longevity Investment Landscape: Leading Investors by Deal Count

Executive Summary

The longevity sector, a rapidly expanding frontier in healthcare and biotechnology, is undergoing a significant transformation, moving from a speculative concept to a robust investment domain. This report provides a comprehensive analysis of the global longevity investment landscape, with a particular focus on the leading investors as measured by the number of deals made. In 2024, global investment in longevity companies surged to $8.49 billion, marking a substantial 220% increase from the previous year, despite a slight decrease in the total number of deals. This trend indicates a maturing market where capital is increasingly concentrated in larger, more strategic investments, particularly within platform technologies and consumer-facing solutions. The United States continues to dominate this sector, accounting for a vast majority of deal volume. Key investors, including GV, ARCH Venture Partners, Casdin Capital, and Khosla Ventures, are actively shaping this dynamic environment, demonstrating a diverse interest ranging from deep biotech research to accessible personalized wellness applications. While the sector shows remarkable growth, a considerable gap remains between current investment levels and the capital required to mitigate age-related diseases, highlighting a vast untapped opportunity for future development and societal impact.

1. Introduction to the Longevity Sector

The pursuit of extended human health and lifespan, once confined to the realm of science fiction, has evolved into a tangible, multi-billion-dollar industry known as the longevity sector. This burgeoning field is fundamentally reshaping the approach to health and wellness, shifting the focus from reactive disease treatment to proactive healthspan extension.

1.1 Defining Longevity: Scope and Key Principles

The longevity sector encompasses a broad spectrum of scientific and technological advancements aimed at prolonging the period of healthy human life, often referred to as "healthspan," and preventing the onset of age-related diseases.¹ This represents a profound paradigm shift from traditional medical practices that typically address illnesses and symptoms as they arise.³ Instead, longevity medicine emphasizes interventions that target the underlying mechanisms of aging itself, biological systems, and overall wellness.¹

Key areas within this sector include anti-aging interventions, regenerative medicine, therapies specifically designed for age-related diseases, and innovative healthy aging technologies.¹ The field is deeply rooted in geroscience, which is the study of the biological processes of aging, and integrates principles of precision, personalized, and preventive (P3) medicine.² Core practices in longevity medicine prioritize preventative care through regular health screenings and early interventions. It advocates for personalized treatment plans, recognizing that individual aging processes vary based on unique genetic makeup, lifestyle, and health history. Furthermore, it adopts a holistic approach to health, considering physical, mental, and emotional well-being, and integrating diverse disciplines such as nutritional optimization, exercise, stress management, and advanced regenerative treatments like stem cell therapy and tissue regeneration.³ The evolution of this field from a "distant fantasy" to a "new multibillion-dollar industry" underscores the significant scientific progress and commercial viability that is now attracting substantial investor interest.¹ The emphasis on extending "healthy life" rather than merely prolonging life at any cost is a critical distinction, aligning with a proactive, value-based healthcare model.¹

1.2 Market Growth and Strategic Significance

The longevity industry has demonstrated active growth, with the market capitalization of 490 publicly traded longevity-focused companies reaching $5.26 trillion as of Q3 2021.⁴ This expansion is anticipated to continue, with broader market projections indicating that the global wellness market, which includes lifestyle medicine and longevity, could exceed $8.5 trillion by 2027.⁵

The strategic importance of this sector is underscored by several converging factors. There is a growing burden of chronic diseases globally, coupled with skyrocketing healthcare costs.⁵ Traditional healthcare systems are heavily burdened by these chronic conditions, with 85% of the $4.9 trillion annual US healthcare expenditure in 2023 attributed to chronic disease management.⁶ In parallel, a new generation of health-conscious consumers is increasingly willing to invest in proactive health tools and preventative measures.⁵ This confluence of factors has led to a fundamental re-evaluation of healthcare economics. Investing in longevity, which aims to prevent or delay the onset of these debilitating and costly conditions, offers a more scalable and potentially more profitable model than solely reacting to established illnesses.⁵ This indicates that investors are not merely pursuing scientific breakthroughs; they are recognizing a substantial, long-term market opportunity to fundamentally reshape healthcare delivery and its associated cost structures. The significant financial incentive to address aging as a root cause of disease represents a largely untapped opportunity within the broader healthcare landscape.⁶

2. Global Investment Trends in Longevity (2023-2024)

Recent data highlights a dynamic and rapidly evolving investment landscape within the longevity sector, characterized by substantial capital inflows and strategic shifts in focus.

2.1 Overall Financing and Deal Volume

Global investment in longevity companies experienced a dramatic increase in 2024, more than doubling to reach a total of $8.49 billion. This figure represents a remarkable 220% growth compared to the $3.82 billion invested in 2023.⁶ Despite this significant surge in overall financing, the total number of deals observed a slight decrease, moving from 331 deals in 2023 to 325 deals in 2024.⁶ The first quarter of 2024 set a strong precedent for the year, attracting $3.74 billion in funding.⁶ Analysis of funding types reveals that later-stage Venture Capital (VC) continued to be the dominant financing mechanism, accounting for approximately one-third (31%) of all funding.⁶

The simultaneous doubling of total financing and a slight reduction in deal count signals a critical development within the market. This pattern suggests a significant increase in the average deal size, indicating a maturing market where investors are making larger, more selective capital commitments. This concentration of capital in fewer, higher-conviction opportunities implies a movement beyond early-stage speculation into a more focused "execution phase".⁶ This trend reflects growing investor confidence in the scalability and long-term viability of specific longevity technologies and business models.

Picture1: Most important figures

2.2 Geographical Concentration of Investment Activity

The United States firmly maintains its position as the global epicenter of longevity innovation and investment. In 2024, the US was home to 57% of all longevity companies and accounted for a dominant 84% of the total deal volume.⁶ In stark contrast, Europe represented 17.3% and Asia 9.8% of longevity-focused companies as of Q3 2021, although investments in China and India have shown an upward trajectory.⁴

The overwhelming dominance of the US in both company formation and deal volume points to a uniquely robust ecosystem for biotechnology and venture capital. This environment benefits from strong research institutions, a deep pool of scientific and entrepreneurial talent, well-established funding mechanisms, and potentially a more favorable regulatory landscape for innovative health technologies. This concentration of activity creates a self-reinforcing cycle, attracting further talent and capital, thereby solidifying the US's leading position in the global longevity sector.

Picture2: Geographical Concentration of Investment Activity

2.3 Dominant Investment Domains and Technologies

Investor preferences within the longevity sector show a clear inclination towards foundational and scalable solutions. In 2024, investors heavily favored platform technologies, with longevity discovery platforms alone attracting over $2 billion, specifically $2.65 billion.⁶ This emphasis on platforms indicates a strategic pivot in investor focus from individual therapeutic candidates to foundational tools and infrastructure that can accelerate the discovery and development of multiple longevity interventions. Such platforms offer scalability and leverage, potentially de-risking investments by supporting a broader pipeline of innovations.

Beyond traditional drug development, there is a strong and growing interest in consumer longevity applications. Notable investments include a $200 million Series D round for ŌURA, a smart ring leader, and a $53 million Series A for Function Health, a personalized prevention platform.⁵ This simultaneous interest in consumer applications suggests a recognition that healthspan extension is not solely dependent on complex biotech solutions but also on accessible, preventative tools that empower individuals and can generate immediate revenue streams outside traditional insurance models.⁵ Among publicly traded longevity companies in Q3 2021, sectors such as PharmTech, P4 Medicine (precision, personalized, preventive, participatory), and Deep Diagnostics were most represented.⁴ This diversification reflects a more mature and commercially astute investment strategy that spans the entire spectrum of longevity solutions.

2.4 Market Maturity and Future Outlook

The 2024 investment report characterizes the longevity sector as transitioning "beyond early-stage hype and into its execution phase".⁶ This assessment reflects growing investor confidence and a more selective, mature market approach. Despite the significant growth observed, current investment levels are noted to "fall short of the capital required to address the problem of mitigating the diseases of aging".⁶ This is particularly evident when comparing longevity investments to the substantial $4.9 trillion annual US healthcare expenditure in 2023, where 85% was directed towards chronic diseases.⁶

This comparison highlights a massive, largely untapped financial opportunity. If successful longevity interventions can significantly reduce the incidence and severity of chronic diseases, the potential for cost savings across global healthcare systems would be enormous. This suggests that while the sector is experiencing rapid expansion, it remains in its nascent stages relative to its potential impact. Investors who can successfully identify and support therapies that effectively address the underlying mechanisms of aging and mitigate age-related diseases are positioned to realize substantial long-term societal and economic benefits. This also implies a future need for increased public-private partnerships and policy adjustments to fully realize the sector's transformative potential.

The following table summarizes key investment statistics for the longevity sector from 2023 to 2024:

Table 1: Key Longevity Investment Statistics (2023-2024)

Metric	2023 Data	2024 Data	Change (2023-2024)
Total Financing	$3.82 billion	$8.49 billion	+220%
Total Deal Count	331 deals	325 deals	-1.8%
Top Financing by Deal Type	N/A	Later Stage VC (31%)	N/A
Longevity Companies by Location	N/A	USA (57%)	N/A
Deals by Location	N/A	USA (84%)	N/A
Top Financing Domain	N/A	Longevity Discovery Platforms ($2.65bn)	N/A

Source: Longevity.Technology 2024 Annual Longevity Investment Report ⁶

3. Leading Investors by Number of Deals in the Longevity Sector

Understanding the most active investors by deal count provides a clear picture of the entities most frequently engaging with and shaping the longevity landscape. This section identifies and profiles these leading players, highlighting their strategic contributions.

3.1 Analysis of Top Venture Capital Firms and Other Active Investors

Based on available data, several prominent investors have demonstrated significant activity in the longevity sector, measured by the number of fundraising deals. The leading investors by deal count include:

• GV: 81 deals ⁸

• ARCH Venture Partners: 52 deals ⁸

• Casdin Capital: 49 deals ⁸

• Polaris Partners: 39 deals ⁸

• Alexandria Venture Investments: 38 deals ⁸

• Khosla Ventures: 38 deals ⁸

• Perceptive Advisors: 32 deals ⁸

• Foresite Capital: 26 deals ⁸

• National Institutes of Health (NIH): 25 deals ⁸

• OrbiMed: 25 deals ⁸

  
  

Beyond these top-ranked entities, other notable active firms with significant fund activity or specific longevity investments include Longevitytech.fund (31 funds), The Longevity Fund (17 funds), and Kizoo Technology Ventures (17 funds).⁸ Specialized firms such as Apollo Health Ventures, Maximon, and Korify Capital are entirely focused on increasing healthspan, indicating a growing specialization within the longevity investment landscape.⁵ Andreessen Horowitz (a16z) also stands out as a significant player, having backed companies like Levels and Thorne HealthTech, which focus on metabolic health and personalized wellness, and leading a $53 million Series A for Function Health.⁵

This composition of active investors reveals a blend of large, established venture capital firms with broad portfolios (e.g., GV, ARCH Venture Partners, Khosla Ventures) and more specialized funds explicitly dedicated to longevity. This indicates that while generalist VCs are increasingly recognizing the vast potential of the longevity sector, dedicated longevity funds are also emerging and playing a crucial role in its development.

Picture3: Top 10 Investors by Deal Count

3.2 Profiles of Key Investors and Their Longevity Portfolios

Detailed examination of some of these leading investors provides further clarity on their strategic approaches within the longevity sector.

• GV (formerly Google Ventures): As the top investor by deal count with 81 deals, GV's extensive activity underscores the significant interest of major tech-affiliated venture arms in the longevity space.⁸ Their high volume of investments suggests a broad strategic interest in the sector's potential to integrate technology and life sciences for health extension.

• ARCH Venture Partners: With 52 deals, ARCH is a prolific investor known for its focus on biotechnology and life sciences, including longevity. The firm was a financial backer of Unity Biotechnology, a company dedicated to developing therapies for age-related diseases, with a particular focus on senescent cells.⁸

• Khosla Ventures: Active with 38 deals, Khosla Ventures has established a strong presence in the longevity sector, particularly in aging biomarkers and consumer longevity platforms.⁸ Their portfolio includes companies such as Modern Age and BioAge Labs.⁵ The firm also recently participated in a $130 million Series B funding round for NewLimit, a longevity-focused biotech company.¹⁰

• Andreessen Horowitz (a16z): While their overall deal count across all sectors is substantial (1,038 from 2018-present) ¹¹, their specific longevity deal count is not directly listed among the top investors by deal volume in the provided data. However, Andreessen Horowitz is explicitly noted for backing companies like Levels and Thorne HealthTech, which are focused on metabolic health and personalized wellness, and for leading a $53 million Series A round for personalized prevention platform Function Health.⁵ This highlights their strategic interest in consumer-facing and platform-based longevity solutions.

• Apollo Health Ventures & Maximon: These firms exemplify the growing trend of venture capital firms that are "entirely focused on increasing healthspan".⁵ Their existence and activity signify the maturing specialization within the longevity investment landscape, where dedicated funds are emerging to address the unique challenges and opportunities of this sector.

• National Institutes of Health (NIH): The presence of NIH among the top investors with 25 deals highlights the crucial role of government funding and grants in advancing foundational longevity research.⁸ Public funding often provides the initial capital for early-stage scientific breakthroughs, which then attract subsequent private investment.

• High-Profile Individual Investors: The longevity sector has also attracted significant interest from influential individual investors. Notable figures such as Jeff Bezos (Amazon) and Peter Thiel (PayPal) have provided support to longevity companies like Altos Labs and Unity Biotechnology, respectively.⁹ Additionally, Michael Dell and Jim Breyer are investors in Arena BioWorks.¹² The involvement of such high-profile individuals lends considerable credibility to the sector, potentially attracting more mainstream capital and validating its long-term potential.

The diverse composition of investors, ranging from traditional biotech VCs to generalist tech VCs and firms focused on consumer applications, illustrates that the longevity sector is not confined to conventional pharmaceutical or biotech drug discovery. It extends into consumer wellness, diagnostics, AI-driven personalization, and lifestyle medicine. This broad appeal attracts a wider range of investors, fostering a more dynamic and diversified investment landscape. The recognition that healthspan extension can be achieved through various pathways, from deep scientific research to accessible consumer products and services, is driving this multifaceted investment approach.

The following table provides a summary of the top longevity investors by their number of fundraising deals:

Table 2: Top Longevity Investors by Number of Fundraising Deals

Rank	Investor Name	Number of Fundraising Deals	Key Investment Focus (where specified)
1	GV	81	Broad strategic interest
2	ARCH Venture Partners	52	Biotech, age-related diseases
3	Casdin Capital	49	N/A
4	Polaris Partners	39	N/A
5	Alexandria Venture Investments	38	N/A
6	Khosla Ventures	38	Aging biomarkers, consumer longevity platforms, longevity biotech
7	Perceptive Advisors	32	N/A
8	Foresite Capital	26	N/A
9	National Institutes of Health (NIH)	25	Foundational research
10	OrbiMed	25	N/A

Source: Spannr.com⁸

4. Strategic Implications and Opportunities

The evolving landscape of longevity investment carries significant strategic implications and presents numerous opportunities for various stakeholders.

4.1 Factors Driving Investor Interest and Activity

Several interconnected factors are fueling the heightened investor interest and activity in the longevity sector:

• Scientific Breakthroughs: Ongoing advancements in biotechnology, genetics, and regenerative medicine are transforming the concept of restorative health from a theoretical possibility into a tangible reality. These scientific leaps are directly fueling investment by demonstrating the feasibility of interventions to slow or reverse aspects of aging.¹

• Economic Imperative: There is a growing understanding that preventive care offers a more scalable and ultimately more profitable model than reactive, acute interventions. Given the immense burden of chronic diseases on global healthcare systems, preventing or delaying these conditions through longevity science presents a compelling economic argument for investment.⁵

• Consumer Demand: A burgeoning wave of health-conscious consumers is increasingly willing to pay for proactive health tools. This demand is particularly strong for solutions that do not rely on traditional insurance models, such as those focused on nutrition, sleep optimization, and metabolic health.⁵ This willingness to pay directly for healthspan extension creates a direct market for innovative products and services.

• Platform-Based Innovation: Startups in the longevity space are increasingly adopting a "vertically integrated platform" approach. These platforms combine diagnostics, behavioral health interventions, and AI-driven personalization, enhancing their long-term defensibility and appeal to investors.⁵ This model allows for comprehensive solutions that address multiple facets of healthspan.

The convergence of these factors suggests that investors perceive longevity as a foundational, multi-decade investment theme rather than a fleeting trend. This perspective implies that while returns may accrue over an extended period, the ultimate market size and societal impact could be immense. This outlook attracts patient capital and strategic investors who are seeking transformative, rather than incremental, returns, recognizing that the underlying biological processes of aging offer a vast and enduring target for innovation.

Picture4: The Path Forward

4.2 Emerging Trends and Untapped Investment Potential

As the longevity sector matures, several key trends are emerging, pointing towards significant untapped investment potential:

• Specialization and Integration: The market is poised for greater specialization within specific longevity sub-sectors, alongside increased integration of various components. This means that companies that once focused on a single aspect, such as wearables or lab testing, are now bundling diagnostics, personalized coaching, and AI-driven recommendations into more comprehensive platforms.⁵ This holistic approach offers more robust and defensible solutions.

• Artificial Intelligence (AI) in Longevity: AI technologies are proving crucial for accelerating drug discovery, development, and testing within the longevity field, as exemplified by companies like Insilico Medicine.⁹ AI is also a vital component in platforms that combine diagnostics with personalized health strategies.⁵ Its role in processing vast datasets and identifying novel therapeutic targets will only grow.

• Regenerative Medicine Growth: The regenerative medicine market, a key component of the broader longevity landscape, is projected for substantial growth, with a Compound Annual Growth Rate (CAGR) of 16.81% from 2025 to 2034.¹³ North America led this market in 2024, driven by increasing adoption of personalized medicine and collaborations between biotech companies and government institutions.¹³ This sub-sector, focused on repairing and rejuvenating aging tissues, holds immense promise for healthspan extension.³

• Public Sector and Philanthropic Capital: The involvement of entities like the National Institutes of Health (NIH) ⁸ and the UK Government, which announced a National Wealth Fund to invest in future industries including life sciences and regenerative medicine ¹⁴, indicates a growing recognition of longevity as a public health priority. This trend could unlock more blended finance models and large-scale research initiatives, further accelerating progress.

The diverse nature of investment across biotech, consumer technology, artificial intelligence, and governmental funding highlights the inherently interdisciplinary nature of successful longevity solutions. These solutions require expertise and capital from a wide array of fields. Investors who can effectively navigate and connect these different domains—for example, a biotech VC collaborating with an AI fund, or a consumer health investor partnering with a diagnostics company—are best positioned for success. This also suggests that the most impactful startups will likely be those capable of effectively integrating multiple technologies and approaches to deliver comprehensive healthspan benefits.

4.3 Recommendations for Stakeholders

To capitalize on the opportunities within the longevity sector and drive its continued growth, specific recommendations are pertinent for key stakeholders:

• For Investors: It is advisable to focus on platform technologies and integrated solutions, as these offer greater scalability and long-term defensibility. Exploring opportunities in consumer longevity applications can diversify portfolios and tap into immediate revenue streams. Investors should adopt a long-term perspective, recognizing the multi-decade nature of longevity investments and their potential for significant societal impact alongside financial returns. Continuous monitoring of regulatory developments is also crucial, as policy frameworks can either accelerate or impede market growth.

• For Startups: Developing comprehensive, vertically integrated platforms that address multiple facets of healthspan is recommended. Leveraging advanced technologies such as AI and data analytics for personalized solutions will be critical for competitive advantage. Startups should strategically seek partnerships with both generalist and specialized longevity investors, understanding their distinct investment theses and aligning with those that best fit their development stage and strategic goals.

• For Policymakers: Recognizing aging as a treatable condition and a public health priority is a fundamental step. Policymakers should actively invest in foundational research, similar to the role played by the NIH. Furthermore, establishing clear and supportive policy frameworks that incentivize preventive care and streamline the approval process for safe and effective longevity therapies can unlock the significant economic benefits associated with extended healthspan and reduced chronic disease burden.

Conclusion

The longevity sector is rapidly transitioning from a nascent, specialized field to a mainstream investment theme, propelled by groundbreaking scientific advancements, a compelling economic imperative, and burgeoning consumer demand. The significant increase in total financing in 2024, coupled with a slight reduction in deal count, signals a maturing market. This indicates a strategic shift towards larger, more selective investments, particularly in foundational platform technologies and accessible consumer-facing solutions. The United States maintains its dominant position as a global hub for innovation and investment in this space.

Leading investors, including prominent venture capital firms like GV, ARCH Venture Partners, Casdin Capital, and Khosla Ventures, alongside increasingly specialized longevity funds, are actively shaping this dynamic landscape. Their diverse investment strategies, spanning deep biotech research to personalized wellness applications, underscore the interdisciplinary nature of the field. Despite the impressive growth, a substantial investment gap persists when compared to the vast economic burden imposed by age-related diseases. This gap highlights an immense, largely untapped potential for both significant financial returns and profound societal benefits through the effective mitigation of aging. The future trajectory of longevity investment will undoubtedly be characterized by continued innovation in foundational tools, strategic integration across diverse technological domains, and a collaborative effort among all stakeholders to extend healthy human life for the betterment of global society and economy.

Works cited

1. The Future of Aging and Longevity | Deloitte US, accessed on June 27, 2025, https://www.deloitte.com/us/en/Industries/life-sciences-health-care/articles/longevity-science.html

2. Longevity Industry Landscape Overview Volume II: The Business of Longevity Markets, Trends, Sectors, accessed on June 27, 2025, http://data.longevity.international/data/pdf/Longevity-Industry-Landscape-Overview-2018-V2-The-Business-of-Longevity.pdf

3. Understanding Longevity and Anti-Aging Medicine - Live Without Lines Med Spa, accessed on June 27, 2025, https://www.lwlmedspa.com/understanding-longevity-and-anti-aging-medicine

4. Investment Digest - Longevity Industry Q3 2021 - EBAN, accessed on June 27, 2025, https://www.eban.org/wp-content/uploads/2021/11/Investment-Digest-Longevity-Industry-Q3-2021-1.pdf

5. The Longevity Bet: Why VCs Are Pouring Capital Into Lifestyle Medicine, accessed on June 27, 2025, https://www.thelotuscapital.com/the-longevity-bet-why-vcs-are-pouring-capital-into-lifestyle-medicine/

6. Longevity investment more than doubled to $8.5bn in 2024 - PR Newswire, accessed on June 27, 2025, https://www.prnewswire.com/news-releases/longevity-investment-more-than-doubled-to-8-5bn-in-2024--302453871.html

7. Longevity Investment More Than Doubled to $8.5bn in 2024 - Lifespan.io, accessed on June 27, 2025, https://www.lifespan.io/news/longevity-investment-more-than-doubled-to-8-5bn-in-2024/

8. Longevity Investors - Spannr, accessed on June 27, 2025, https://spannr.com/investors

9. The top 11 longevity companies leading the quest for life extension - Ross Dawson, accessed on June 27, 2025, https://rossdawson.com/futurist/companies-creating-future/top-11-longevity-companies-life-extension-immortality/

10. Most-Active US Investors: Khosla, Accel Top May Ranking - Crunchbase News, accessed on June 27, 2025, https://news.crunchbase.com/venture/most-active-us-investors-may-2025-khosla-accel/

11. The most active VC investors in startups - PitchBook, accessed on June 27, 2025, https://pitchbook.com/blog/top-vc-investors-in-startups

12. 5 Private Longevity Research Companies (Updated 2024) - Nasdaq, accessed on June 27, 2025, https://www.nasdaq.com/articles/5-private-longevity-research-companies-updated-2024

13. Regenerative Medicine Market Size to Hit USD 169.55 Billion by 2034 - BioSpace, accessed on June 27, 2025, https://www.biospace.com/press-releases/regenerative-medicine-market-size-to-hit-usd-169-55-billion-by-2034

14. Regenerative Medicine Market Report 2025: Key Insights & Innovations, accessed on June 27, 2025, https://www.startus-insights.com/innovators-guide/regenerative-medicine-market-report/